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1. Restless Legs Syndrome: Clinical Features, Diagnosis and 
Pathophysiology. 
Restless legs syndrome (RLS) is a somatosensory disorder that is clinically 
diagnosed according to the four main criteria established by the 
International Restless Legs Syndrome Study Group (IRLSSG) (Walters AS, 
1995), and reviewed in 2003 (Allen RP et al, 2003): an urge to move the 
legs, usually associated with unpleasant leg sensations; induction or 
exacerbation of symptoms by rest; symptom relief on activity; diurnal 
fluctuations in symptoms with worsening in the evening and at night. The 
three supportive criteria include periodic limb movements (PLM), 
therapeutic response to dopaminergic (DAergic) agents, and a family history 
of the disorder. The most important associated feature is sleep disturbance. 
The second common finding is a progressive course. The third finding is the 
absence of clear-cut signs of other neurological diseases in patients with 
idiopathic RLS (Figure 1). 
As well as the sensory features, patients may experience motor features, in 
addition to the voluntary movements they make to alleviate discomfort. 
These involuntary movements may arise in sleep or while awake, and 
typically involve brief repetitive movements of the legs, ranging from subtle 
extension of the hallux to flexion of the hip, knee, and ankle. About 80% of 
patients with the syndrome experience these movements labelled periodic 
limb movements in sleep (PLMS) and wakefulness (PLMW). These 
movements can result in arousals, leading to unrefreshing sleep and sleep 
maintenance insomnia (Trenkwalder C et al, 2005; Allen RP et al, 2003; 
Leschziner G and Gringras P, 2012). 
RLS prevalence in the general population is 10–12% (with a range of 5–
20% in different studies), increasing with age and among women 
(Trenkwalder C et al, 2005; Allen RP et al, 2003).  
RLS may be idiopathic or symptomatic. Idiopathic disease seems to have a 
strong genetic component, with a family history in 18.5-60% of patients 
(Rangarajan S et al, 2007; Vogl FD et al, 2006). RLS has been associated 
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with a wide variety of conditions, most often iron deficiency and uraemia. 
Other disease associations include cardiovascular disease, obesity, diabetes, 
rheumatological disorders, peripheral neuropathy, radiculopathy, 
Parkinson’s disease, multiple sclerosis, Charcot-Marie-Tooth disease, and 
spinal cord lesions. However, many of these diseases were not seen in all 
studies, and the strengths of these associations are unclear (Bassetti C et al, 
2001; Trenkwalder C et al, 2005; Leschziner G and Gringras P, 2012). 
The diagnostic process requires special attention to exclude other conditions 
that may resemble RLS, so-called “RLS mimics”, which include akathisia, 
nocturnal leg cramps, peripheral neuropathy, lumbosacral radiculopathy, 
painful legs and moving toes, growing pains, and attention deficit 
hyperactivity disorder (Hening WA et al, 2009). 
A useful diagnostic tool is the suggested immobilization test, that evaluates 
periodic leg movements (PLM) and self-reported sensory symptoms for 
people who are instructed to remain still for 1 h while sitting on a bed with 
their legs outstretched (Michaud M et al, 2002). Polysomnography allows 
accurate assessment of PLMS, scoring them only if they occur in a series of 
four consecutive movements lasting 0.5-5 s, have an amplitude of one 
quarter or more of the toe dorsiflexion during calibration and are separated 
by intervals of 4-90 s. PLMS occur during stages 1-2 of NREM sleep, 
diminish during stages 3-4 and nearly always disappear during REM sleep. 
An index (number of PLMS per hour of sleep) greater than 5 for the entire 
night is considered pathologic and is supportive, although not specific, of 
the diagnosis of RLS (Zucconi M et al, 2006).  
Since RLS is primarily a subjective disorder, a subjective scale of RLS 
symptoms represents the optimal instrument to measure disease severity for 
clinical assessment, research or therapeutic trials. In 2003, the IRLSSG 
proposed and validated a rating scale, consists of ten questions, whose total 
score progresses from 0 to 40 with the degree of disease severity (Walters 
AS et al, 2003).  
The pathophysiology of RLS is poorly understood. Many regions of the 
nervous system from the periphery to the cortex contain structures involved 
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in somatosensory perception and in the generation of movement 
(Trenkwalder C and Paulus W, 2010). Electrophysiological studies suggest 
that PLM are involuntary and are organized at the brainstem or spinal level 
(Trenkwalder C et al, 1996). Patients with PLMS, with or without 
associated RLS, may have abnormal blink reflexes (Briellmann RS et al, 
1996). H-reflexes and H-reflex modulation modulation (Martinelli P and 
Coccagna G, 1976; Rijsman RM et al, 2005; Scaglione C et al, 2008) and 
flexor reflex (Bara-Jimenez W et al, 2000) are impaired suggesting a 
brainstem or more rostral dysfunction leading to enhanced spinal 
excitability. Transcranial magnetic stimulation (TMS) studies have shown 
abnormal motor cortex excitability in RLS, which is reversible by dopamine 
agonist administration (Nardone R et al, 2006; Kutukcu Y et al, 2006; 
Gorsler A and Liepert J, 2007; Rizzo V et al, 2009). 
Functional MRI (fMRI) studies in RLS patients demonstrated an activation 
of the thalamus (legs discomfort), cerebellum (legs discomfort and PLM), 
red nuclei and brainstem (PLM) (Bucher SF et al, 1997), and using only a 
motor paradigm, of the thalamus, putamen, middle frontal gyrus and 
cingulate gyrus (Astrakas LG et al, 2008). Recently, activation of the 
striatofrontolimbic area during night-time episodes of sensory leg 
discomfort and PLMs was reported and claimed to represent the 
neurofunctional substrate mediating the repetitive compulsive movements 
seen in RLS (Margariti PN et al, 2012). The hypothesis that dysfunction of 
the limbic system plays a role in the pathophysiology of idiopathic restless 
legs syndrome was also supported by a proton magnetic resonance 
spectroscopy study by Rizzo et al showing an abnormal medial thalamus 
metabolism in idiopathic RLS patients (Rizzo G et al, 2012). 
MR studies using advanced techniques such as voxel-based morphometry 
(VBM) and diffusion tensor imaging (DTI) looked for structural brain 
abnormalities in idiopathic RLS patients but reported contrasting results. 
Some studies disclosed regional brain changes, but affected brain structures 
differed in some studies (Etgen T et al, 2005; Unrath A et al, 2007; Hornyak 
M et al, 2007; Connor JR et al, 2011; Unrath A et al, 2008), while others 
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yielded no specific brain alterations (Celle S et al, 2010; Comley RA et al, 
2012; Rizzo G et al, 2012) supporting the role of functional or metabolic 
impairment in RLS.  
All these studies are consistent with a subcortical dysfunction. Therefore, 
RLS appears to be a complex movement disorder affecting several levels of 
the neuraxis, although the precise anatomic location of this dysfunction 
remains unsettled (Barrière G et al, 2005). However, there is evidence for 
impairment of sensorimotor processing at the level of the cortex and the 
spinal cord, suggesting altered subcortical/supraspinal control. 
Iron deficiency seems to be implicated in RLS pathophysiology. Although 
iron deficiency alone is not sufficient to cause restless legs syndrome—and 
neither is it necessary—precipitation or exacerbation of symptoms with 
venesection is well described, and serum ferritin correlates inversely with 
symptom severity (Tobiasson M et al, 2010). Magnetic resonance imaging 
and cerebrospinal fluid studies and autopsy specimens of substantia nigra 
have shown that brain iron stores are reduced in patients with RLS (Earley 
CJ et al, 2000; Connor JR et al, 2003). Iron is an essential cofactor for 
tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis) and 
seems to play a crucial role in dopamine metabolism (Allen RP, 2004). 
Dopaminergic system involvement is highly probable because effective 
treatment with dopamine agonists has been confirmed by controlled trials, 
whereas dopamine antagonists worsen symptoms or may even elicit RLS 
(Barrière G et al, 2005). However, it is unclear whether the dopaminergic 
system is hypo- or hyperactive in RLS. PET and SPECT studies revealed 
controversial results on the pre- and post-synaptic dopaminergic 
neurotransmission system. Almost all have focused on the striatum, a brain 
region receiving dense dopaminergic innervations, showing slightly reduced 
binding or no difference of both presynaptic ([123I]βCIT, [123I]IPT or 
[99mTc]TRODAT-1 in SPECT studies and 18F-dopa in PET studies) and 
postsynaptic D2 radioligand ([123I]IBZM in SPECT studies and 11C-
raclopride in PET studies) in RLS patients compared with control subjects 
(Wetter TC et al, 2004; Hilker R et al, 2006). Taken together, these results 
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suggest that at nigrostriatal pathway level the membrane dopamine 
transporter and postsynaptic D2-receptor seem to be either unchanged or 
mildly reduced in patients with idiopathic RLS. In addition to 11C-raclopride 
in striatal regions, another PET study investigated other extrastriatal 
dopaminergic regions by FLB 457 (a new postsynaptic high-affinity D2 
radioligand) disclosing a higher binding potential in patients than controls in 
the limbic and associative part of the striatum, medial and posterior part of 
thalamus, anterior cingulate cortex and insula, all belonging to the medial 
nociceptive system which is thought to regulate the affective-motivational 
component of pain. The authors sustained the hypothesis of hypoactive 
dopaminergic neurotransmission associated with receptor up-regulations 
(Cervenka S et al, 2006). An involvement of the medial nociceptive system 
was supported also by a PET study with [11C]diprenorphine, a non-selective 
opioid receptor radioligand, which found regional negative correlations 
between ligand binding and RLS severity in areas serving the medial pain 
system (medial thalamus, amygdala, caudate nucleus, anterior cingulate 
gyrus, insular cortex and orbitofrontal cortex) (von Spiczak S et al, 2005). 
A recent PET study in RLS showed lower dopamine-2 receptor (D2R) 
binding potentials (BP) in putamen and caudate, interpreted as an increase 
in synaptic DA (Earley CJ et al, 2013). Several lines of investigation 
suggest the pre-synaptic DAergic activity may be increased in RLS and thus 
could result in an increase in synaptic DA. CSF analysis in RLS disclosed 
an increase in 3-O-methyldopa (Earley CJ et al, 2006; Allen et al, 2008), 
found as a by-product of COMT metabolism of L-DOPA when the latter is 
in excess (Cooper JR et al, 2003). One interpretation of the CSF results is 
that they represented an increase in tyrosine hydroxylase (TH) activity and 
L-DOPA production (Earley CJ et al, 2006). This is supported by the 
finding of increased total TH, and in the more enzymatic active form, 
phosphorylated TH, in the autopsy brains of RLS patients (Connor JR et al, 
2009). 
Regarding dopaminergic structures beneath the basal ganglia, several 
studies have focused on the role of the dorso-posterior hypothalamic 
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dopaminergic A11 cell group in RLS, particularly under conditions of iron 
deprivation (Qu S et al, 2007). The A11 cell group represents the largest and 
possibly the only source of spinal DA, and its spinal projections modulate 
sensory inputs and sympathetic drive, predominantly with inhibitory action 
through D2 and especially D3 receptors (Clemens S et al, 2006). This theory 
was supported by animal models showing that D3 receptor knockout 
(D3KO) mice were hyperactive and manifested an increased wakefulness 
across the rest-activity cycle (Accili D et al, 1996; Hue GE et al, 2003) and 
that locomotor activities were significantly increased in A11-lesioned mice 
compared with controls (Ondo WG et al, 2000; Qu S et al, 2007). 
In summary, even if cerebral metabolism in RLS probably reflects a 
dysfunction of the central dopaminergic system, it remains to be determined 
whether these alterations affect mainly the nigrostriatal and/or other central 
dopaminergic systems like the diencephalospinal or mesolimbic pathway 
and whether they are the primary mechanisms or only secondary 
phenomena within the manifestation of RLS symptoms.   
2. Nocturnal Eating Disorders: Sleep-Related Eating Disorder 
and Night Eating Syndrome. 
Night-time in humans is typically characterized by a prolonged period of 
fasting associated with sleep. Abnormal eating during the main sleep period 
has been categorized as either sleep-related eating disorder (SRED) or night 
eating syndrome (NES). According to the revised International 
Classification of Sleep Disorders (ICSD-2), SRED is a parasomnia 
consisting of ‘‘recurrent episodes of involuntary (out of control) eating and 
drinking during arousal from sleep with problematic consequences” 
(American Academy of Sleep Medicine. The International Classification of 
Sleep Disorders, 2nd ed: Diagnostic and coding manual. Westchester, IL: 
American Academy of Sleep Medicine; 2005) (Figure 2) such as 
consumption of peculiar combinations of food or high calorie foods, bizarre 
and toxic substances (frozen food, uncooked spaghetti, cat food, egg shells, 
coffee grounds, sunflower shells, buttered cigarettes, glue, and cleaning 
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solutions), morning anorexia, dangerous food preparation behaviour, sleep-
related injury and weight gain (Howell MJ et al, 2008). Often, patients 
cannot be easily awakened and the eating is poorly recalled, thus SRED 
resembles sleep-walking. 
The majority (60-83%) of reported cases of SRED are female (Winkelman 
JW, 1998) with a chronic course of the disorder (Schenck CH et al, 1991). 
Polysomnography (PSG) has been used to characterize SRED. Most 
commonly, eating behaviour arises from NREM sleep and the majority of 
patients demonstrated excessive periodic limb movements in sleep (PLMS) 
(>5/h) and rhythmic masticatory muscle activity (RMMA) (Vetrugno R et 
al, 2006). 
An associated primary sleep disorder, particularly sleep-walking and RLS, 
was identified in 68% and 13% of SRED patients, respectively (Schenck CH 
et al, 1993). Furthermore, SRED has been associated with psychotropic 
medications, in particular the benzodiazepine receptor agonist zolpidem, 
tricyclic antidepressants, anticholinergics, lithium, triazolam, olanzapine, 
and risperidone (Morgenthaler TI and Silber MH, 2002; Schenck CH and 
Mahowald MW, 1994). 
The pathophysiology of SRED in unclear. SRED could be construed as a 
disorder whereby sleep-related motor and autonomic arousal processes 
happen to stimulate the appetitive-feeding pathways and elicit a time-
inappropriate compulsive feeding behaviour (Vetrugno R et al, 2006). The 
beneficial effects of dopaminergic agents, an association with increased 
motor activity (rhythmic masticatory-muscle activity/RMMA, PLMS, RLS) 
suggestive of a generalized motor disinhibition probably of dopaminergic 
origin, and compulsive food-seeking episodes (dysfunction of dopaminergic 
system at the mesolimbic level) could suggest a pathogenic role for the 
dopaminergic system in nocturnal eating disorders (Vetrugno R et al, 2006). 
NES is the other category of night-time eating. NES has no entry in the 
ICSD-2 classification, but diagnostic criteria for NES, different from the 
ICSD-2 criteria for SRED, have been proposed (Birketvedt GS et al, 1999). 
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NES could be considered an abnormality in the circadian rhythm of meal 
timing with a normal circadian timing of sleep onset. The disorder was 
thought to be a response to stress, and was originally studied among obese 
persons refractory to standard weight loss treatment (Howell MJ et al, 
2008). For a diagnosis of NES all of Birketvedt et al’s criteria must be met, 
i.e. evening hyperphagia, nocturnal awakenings, nocturnal hyperphagia, 
morning anorexia, absence of other eating disorders behaviour (Birketvedt 
GS et al, 1999). Recently Birketvedt et al’s criteria were reviewed. The core 
criterion for NES is an abnormally increased food intake in the evening and 
night-time, manifested by (1) consumption of at least 25% of intake after the 
evening meal, and/or (2) nocturnal awakenings with ingestions at least twice 
per week. Awareness of the eating episodes is required, as is distress or 
impairment in functioning. Three of the following core features must also be 
endorsed: (1) morning anorexia, (2) a strong desire or urge to eat between 
dinner and sleep initiation and/or upon awakening at night from sleep, (3) 
sleep onset and maintenance insomnia, (4) the belief that one must eat in 
order to get to sleep, and (5) depressed mood or lowering of mood in the 
evening and night-time. These criteria must be met for a minimum duration 
of three months. The absence of other medical and/or psychiatric disorder 
was also required (Allison CK et al, 2010) (Figure 3). 
Different studies have indicated a prevalence of NES of approximately 1.5% 
in adult populations (Striegel-Moore RH et al, 2005). 
The relationship of SRED with NES is still unclear (Vinai P et al, 2012). 
SRED and NES share some overlapping features (nocturnal awakenings to 
eat with loss of control over consumption, sleep fragmentation and morning 
anorexia). Evening hyperphagia and sleep onset insomnia are typical of 
NES but not of SRED. Some authors have also considered impaired 
consciousness and subsequent amnesia for the eating episodes to be the 
major feature differentiating SRED from NES (Winkelman JW, 1998; 
Vetrugno R et al, 2006; Provini F et al, 2009). However, the level of 
consciousness during eating episodes in SRED may vary among episodes 
within the same night and from night-to-night over the longitudinal course 
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of the disorder (Winkelman JW, 2006). There is also a strong association 
between a diminished level of awareness and a history of sleepwalking and 
medications or substance use/abuse (Vetrugno R et al, 2006). Difficulties 
with the classification of SRED on the basis of impaired consciousness 
during the eating episodes are also highlighted in the revised International 
Classification of Sleep Disorders-2, which acknowledges that eating 
episodes in SRED may be accompanied by either clear or clouded 
consciousness. “Recurrent episodes of involuntary eating and drinking 
occurring during the main sleep period” is the primary criterion of SRED. 
This criterion does not mention clouded awareness or memory of eating 
and, in effect, incorporates NES into SRED. The critical issue of the 
relationship between the two disorders is ignored (American Academy of 
Sleep Medicine. The International Classification of Sleep Disorders, 2nd ed: 
Diagnostic and coding manual. Westchester, IL: American Academy of 
Sleep Medicine; 2005; Vetrugno R et al, 2006; Stunkard AJ et al, 2009). 
SRED probably represents a heterogeneous syndrome and it is currently still 
debated whether SRED and NES represent separate entities or simply two 
poles of a pathophysiologic continuum. Given the difficulties in the 
classification of SRED and/or NES and their relationship, this study will use 
the general term nocturnal eating disorders (NED). 
3. Association of Restless Legs Syndrome with Nocturnal 
Eating Disorder. 
A recent case-control study adopting validated criteria in a sufficiently large 
population showed a significant association between SRED and RLS, with a 
lifetime SRED prevalence of 33% in RLS patients and 1% in the control 
group (Provini F et al, 2009). An association between nocturnal eating and 
RLS had already been observed in an uncontrolled case series by Ekbom, 
whose first RLS description reported that RLS patients ‘‘could get up, walk, 
go into the kitchen and get something to eat’’ (Ekbom KA, 1960) and by 
Schenck et al. (Schenck CH et al, 1993) and Vetrugno et al. (Vetrugno R et 
al, 2006). 
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The nature of the association between SRED and RLS and its underlying 
mechanisms remain unclear. The eating behaviour could represent a sort of 
‘‘killing time’’ behaviour performed in an attempt to recapture sleep, as 
already suggested (Manni R et al, 1997). Nocturnal eating more often (but 
not invariably) appeared after RLS onset, suggesting a pathophysiological 
mechanism related to the dopaminergic system, similar to RLS: beneficial 
effects of dopaminergic agents in SRED, association of nocturnal eating 
with increased motor activity (PLM, RMMA) and a demonstration of 
nocturnal eating/drinking syndrome secondary to neuroleptic-induced RLS 
(Horiguchi J et al, 1999), emphasized this hypothesis. On the other hand, 
drugs used to control RLS could be related to the onset of nocturnal eating, 
especially since amnestic SRED has been reported after zolpidem 
(Morgenthaler TI and Silber MH, 2002) and since benzodiazepines are 
recognized triggers for the onset of parasomnias. Furthermore, the patients 
often described the nocturnal eating episodes as occurring without hunger 
and associated with a feeling of being ‘‘out of control’’, in some way 
comparable to a compulsive behaviour. Interestingly, Provini et al’s study 
analysing the psychopathological profile of healthy subjects and RLS 
patients with and without nocturnal eating, showed that pathological values 
on the MOCI (Maudsley Obsessive Compulsive Inventory), a scale that 
specifically measures obsessive/compulsive characteristics, increased from 
controls to RLS patients without SRED to RLS with SRED. Conversely, no 
significant differences in demographics, habit features or clinical data, 
particularly RLS characteristics (including age at onset, positive family 
history, illness severity, medications for RLS symptoms), were found in the 
sample of RLS patients with SRED compared to RLS without SRED 
(Provini F et al, 2009). 
Regarding psychiatric comorbidity and nocturnal eating in RLS, another 
study by the same group demonstrated an increased prevalence of current 
and lifetime nocturnal smoking (NS) in patients with RLS and in particular 
in RLS patients with nocturnal eating disorder (Provini F et al, 2010). 
Excessive smoking qualifies as a distinct psychiatric disturbance, with 
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affected patients displaying higher rates of anxiety and depression (DSM IV, 
Diagnostic and Statistical Manual of Mental Disorders. IVth ed. American 
Psychiatric Association; 1994). The same study also found that pathological 
obsessive-compulsive scores on the MOCI increased in RLS patients with 
NS, suggesting that NS in RLS could represent a compulsive habit 
behaviour possibly facilitated by the nocturnal arousals characteristic of 
RLS. Obviously, alternative explanations have not been excluded. Nicotine 
has some dopamine-stimulating effects (Corrigall WA et al, 1994), and 
nicotine intake during the night could ease the symptoms and signs of RLS. 
NS could also represent merely a way of killing time in an attempt to 
recapture sleep, since sleep fragmentation and wakefulness during the night 
are more likely to occur in RLS patients than in controls (Provini F et al, 
2010). 
An association with psychiatric disturbances, especially anxiety, depression 
and panic disorder have been reported in both RLS and NED (Picchietti D 
and Winkelman JW, 2005; Winkelman JW et al, 2006; Lee HB et al, 2008; 
Howell MJ et al, 2009). Higher scores for neuroticism and compulsivity 
were also reported in RLS patients (Kalaydjian A et al, 2009; Scholz H et al, 
2011), although most studies explained the possible induction of compulsive 
behaviour in RLS by dopaminergic drugs, particularly DA agonists, 
emphasizing the role of dopaminergic mesolimbic stimulation in the 
reinforcement process of rewarding behavioural sequences (Pourcher E et 
al, 2010). Furthermore, self-perceived stress and sleep problems appear to 
distinguish compulsion-prone patients from the others (Pourcher E et al, 
2010). 
4. Objectives of the Study. 
On the basis of the results of previous studies (Provini F et al, 2009 and 
2010) we hypothesize that nocturnal eating behaviour may represent a real 
obsessive/compulsive trait in RLS, possibly related to dopaminergic 
mechanisms. In addition, the limbic system seems to be implicated in the 
pathophysiology of both RLS and obsessive-compulsive disorder (Margariti 
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PN et al, 2012; Rizzo G et al, 2012; Dichter GS et al, 2012). Therefore, the 
study aimed to evaluate psychiatric comorbidity in RLS patients without 
and with nocturnal eating disorder, untreated with dopamine agonists, 
analysing obsessive-compulsive traits together with mood and anxiety 
disorder, in comparison with a control group. 
Furthermore, for the first time we investigated the two major domains of 
personality, temperament and character, in the three groups of subjects. 
According to Cloninger's biogenetic theory of personality, temperament 
refers to our congenital emotional predisposition. Temperament can be 
defined as the automatic associative response to emotional stimuli that 
determines habits and moods; it represents a trait of personality that is 
heritable, biologically and partly genetically determined, developmentally 
stable, uninfluenced by sociocultural learning, and regulated by limbic 
circuits connecting hippocampus, amygdala, hypothalamus, and related 
subcortical structures. On the other hand, character dimension is what 
people make of themselves intentionally, and refers to the self-awareness 
concepts that influence our voluntary intentions and attitudes. In contrast to 
temperament, character is weakly heritable, but is influenced by 
sociocultural learning. It matures in a stepwise manner in increments from 
infancy through late adulthood, and is regulated by the hippocampal 
formation and cerebral neocortex (Cloninger CR, 1994).  
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1. Subjects. 
Patients with primary RLS (p-RLS) without nocturnal eating disorder 
(NED), and patients with p-RLS with NED were recruited by the Sleep 
Medicine Centre of the IRCCS, Institute of Neurological Sciences, and 
Department of Biomedical and NeuroMotor Sciences, University of 
Bologna, Italy. Healthy control subjects were recruited at the Psychiatry 
Unit of Parma Hospital. 
Exclusion criteria were: 1) secondary forms of RLS; 2) neurological disease 
other than RLS; 3) serious and chronic medical diseases; 4) any psychiatric 
diagnosis, including major mood disorders (depressive illness or bipolar 
disorders), schizophrenia or other psychosis, bulimia nervosa and anorexia 
nervosa, or personality disorders; 5) previous head concussion; 6) dementia 
or mental retardation (IQ < 70); 7) drug or alcohol addiction; 8) any 
condition affecting the ability to complete the assessment, including low 
literacy or denial of informed consent. 
Both patients and controls participated voluntarily in the study and gave 
their informed consent. The local institutional review board approved the 
project. 
2. Procedure. 
Each subject received two semi-structured interviews, each conducted by 
different researchers. The first interview was conducted by a neurologist 
expert in sleep medicine and consisted of three sections: the first collected 
demographic data and assessed general health status, (age, level of 
education, occupation, concomitant diseases, body mass index); the second 
assessed the presence/absence of the diagnostic criteria for p-RLS and for 
NED; the third examined RLS features (age at onset of RLS, positive family 
history of RLS, illness severity of RLS, RLS frequency in the last three 
months, daytime RLS symptoms, medication for RLS symptoms) and NED 
features (age at onset of NED, relationship between RLS and NED onset, 
NED frequency in the last three months). 
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Patients with p-RLS all met the revised criteria of IRLSSG (Allen RP et al, 
2003). Secondary forms of RLS were excluded by exploring a detailed 
history, objective evaluation and using laboratory analyses such as 
haemoglobin, iron, ferritin, transferrin, creatinine, urea and liver enzymes, 
blood glucose, glycated haemoglobin. The severity of p-RLS was assessed 
using the IRLSSG rating scale (Walters AS et al, 2003). 
In the absence of validated instruments specific for the investigation of 
NED, the questionnaire administered in the previous study was used 
(Provini F et al, 2009), including a list of items assembled in two sections: 
the first section comprised seven items being the Italian translation of the 
International Criteria for SRED (American Academy of Sleep Medicine. The 
International Classification of Sleep Disorders, 2nd ed: Diagnostic and 
coding manual. Westchester, IL: American Academy of Sleep Medicine; 
2005); the second section contained five items, a translation of the revised 
criteria for NES (Birketvedt GS et al, 1999). All p-RLS with NED met the 
criteria for SRED, two patients also those of NES. 
The second interview was conducted by a psychiatrist: a first section was 
based on the Diagnostic and Statistical Manual of Mental Disorders 4th 
edition, revised text (DSM-IV-TR) (American Psychiatric Association, 
2000) using the SCID-I-DSM-IV-TR (First, Spitzer, Gibbon, & Williams, 
2002) and SCID-II-DSM-IV-TR (First, Spitzer, Gibbon, Williams, & 
Benjamin, 1996) to evaluate the presence of the psychiatric disorders 
considered exclusion criteria; a second section assessed family history of 
psychiatric disorder, anxiety disorders and depressive symptoms, 
compulsive-obsessive symptoms and personality traits (temperament and 
character). The self-administered and interviewer-administered 
questionnaires used were: 
- Hamilton Depression Rating Scale (HAM-D) (Hamilton M, 1960; 
Hedlund JL and Viewig BW, 1979): also called the Hamilton Depression 
Rating Scale (HDRS), abbreviated HAM-D, is a 17-item clinician-rated 
scale used to provide an indication of depression, and as a guide to evaluate 
recovery (Hamilton M, 1960). The questionnaire is designed for adults and 
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is used to rate the severity of their depression by probing mood, feelings of 
guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight 
loss, and somatic symptoms. 
- Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959): the HAM-A 
is a 14-item clinician-rated scale used to measure prolonged state anxiety. 
- State-Trait Anxiety Inventory (STAI) (Spielberger CD et al, 1983): the 
STAI is divided into two sections, each having twenty questions, designed 
for measuring state anxiety, or anxiety about an event, and trait anxiety, that 
evaluated the frequency of how a person “generally feels” anxious.  
Respondents are asked to rate each item on a four-point Likert-type scale, 
ranging from 1 (almost never) to 4 (almost always). The total score ranges 
from 20 to 80, with higher scores indicating greater trait anxiety. 
- Maudsley Obsessive Compulsive Inventory (MOCI) (Hodgson RJ and 
Rachman S, 1977) to measure obsessive-compulsiveness. The MOCI is a 30 
true-false item scale designed to assess obsessive-compulsive symptoms. 
The scale measures four dimensions of obsessive-compulsive symptoms: 
checking compulsions, washing/cleaning compulsions, slowness, and 
doubting. 
- Temperament and Character Inventory - revised (TCI) for analysis of 
personality traits: the TCI is a 240-item, self-administered, true/false 
questionnaire measuring seven personality dimensions based on Cloninger's 
psychobiological model of personality. This model claims that human 
personality is determined by temperament and character and assumes a 
seven-factor structure of personality (Cloninger CR, 1994). TCI includes 
four temperament dimensions (novelty seeking, harm avoidance, reward 
dependence and persistence) and three character dimensions (self-
directedness, cooperativeness and self-transcendence). Novelty seeking is a 
tendency to respond actively to novel stimuli. It involves impulsiveness in 
decision-making. Harm avoidance is the tendency to respond intensely 
(behavioural inhibition) to signals of punishment or non-reward, and 
involves anticipatory worry on the possibility of problems, insecurity, and 
poor initiative. Reward dependence reflects an intense response to reward 
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and maintenance of rewarded behaviour. Individuals with high scores on 
reward dependence are described as sentimental, attached and easily 
influenced by others. Persistence represents the maintenance of behaviour in 
the face of frustration: it involves overachieving but also rigidity. Self-
directedness expresses the ability to control, regulate, and adapt one’s 
behaviour in order to achieve personal goals. Cooperativeness is the 
tendency to identify with and accept other individuals. It involves empathy, 
helpfulness and compassion. Self-transcendence expresses the degree of 
spiritual acceptance and identification with the wider world and also the 
acceptance of ambiguity and uncertainty. Items are rated on a five point 
Lickert's scale from “definitely false” (1) to “definitely true” (5). 
3. Statistical Analysis. 
Statistical differences in the main demographic, clinical, and psychometric 
variables were tested among the three groups (p-RLS without NED, p-RLS 
with NED and controls). χ2 test was used for categorical variables. Kruskal-
Wallis test, followed by Mann-Whitney U test for pair-wise comparisons, 
was used for ordinal variables. One-way ANOVA, followed by post-hoc 
LSD test for pair-wise comparisons, was used for continuous variables. 
Pearson’s Correlation was used for correlation analysis. For all tests P 
values were considered significant if <0.05 after the application of the 
appropriate Bonferroni correction for multiple comparisons. 
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1. Subjects: Demographic and Clinical Data. 
Ten patients with primary RLS (p-RLS) without nocturnal eating disorder 
(NED), ten patients with p-RLS with NED and ten healthy control subjects 
(age 52±6, mean ± SD; 53±11 and 52±10, respectively; all females. P=0.9) 
were recruited. 
The characteristics of the ten p-RLS patients without NED, the ten p-RLS 
patients with NED and the ten controls are listed in Table 1. Age, level of 
education, occupation, concomitant diseases, and body mass index did not 
significantly differ among the three groups (all P>0.05). 
The mean age (±SD) at onset of p-RLS was 39±14 years for p-RLS patients 
without NED and 42±16 for p-RLS patients with NED (P=0.7). Seven p-
RLS patients without NED and four p-RLS patients with NED had a 
positive RLS family history (P=0.37). The mean (±SD) IRLSSG score was 
17±10 and 19±13 in p-RLS patients without and with NED, respectively 
(P=0.8). In the last three months, nine patients with p-RLS without NED 
had RLS symptoms every day and one patient had symptoms two to three 
times/week. In the p-RLS with NED group, five patients had symptoms 
every day, four patients had symptoms two to five times/week and one 
patient had symptoms more rarely (2-3 times/year) (P=0.07). 
Daytime RLS symptoms were present in seven and in five RLS patients 
without and with NED, respectively (P=0.65). No patient was being treated 
for symptoms of RLS during the period of interviews (Table 1). 
In the patients with p-RLS with NED the mean age (±SD) at onset of NED 
was 41±17 years. NED began one to 14 (mean 6) years after RLS onset in 
four patients, NED onset preceded RLS symptoms by eight to 17 (mean 
10.6) years in three patients, two patients reported the concomitant onset of 
NED and RLS, while NED onset was unknown in one patient (Table 2). 
In the last three months, two patients had nocturnal eating episodes every 
night, six patients had nocturnal eating episodes one to five times/week and 
two patients had nocturnal eating episodes one-two times/month. Nocturnal 
eating episodes could recur several times per night (Table 2). 
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2. Psychopathological Profile. 
 
2.1 Family History of Psychiatric Disorder 
Family history of psychiatric disorder did not significantly differ among the 
three groups (three p-RLS patients without NED, four p-RLS patients with 
NED and three controls had a positive family history of psychiatric disorder; 
P=0.86). 
 
2.2 Depression and Anxiety Disorder 
ANOVA test showed that the severity of depression scale resulting from the 
Hamilton-D did not differ (P=0.7) among the three groups of subjects, 
whereas the Hamilton-A scores significantly differed among the three 
groups (P=0.0002). Furthermore, a significant difference was evident for the 
STAI-Y Trait scores (P=0.043) but not for STAI-Y State scores (Table 3). 
Post-Hoc testing showed that the p-RLS patients without and with NED had 
significantly higher HAM-A (P=0.018 and P<0.0001, respectively) and 
STAI-Y Trait scores (P=0.028 and P=0.040, respectively) than controls. 
HAM-A and STAI-Y Trait scores did not significantly differ between p-
RLS patients with and without NED (P=0.09 and P=1, respectively)  
(Figure 4 and 5). No correlation was found with RLS or NED clinical 
characteristics. 
 
2.3 Maudsley Obsessive Compulsive Inventory 
ANOVA test showed that the three groups had significantly different scores 
on MOCI scale total (P=0.004), doubting (P<0.0001) and checking 
compulsions (P=0.03) (Table 4). Post-hoc test showed that p-RLS patients 
with NED compared to controls had significantly higher MOCI scale total 
(P=0.002), doubting (P<0.0001) and checking compulsion (P=0.018) scores. 
In p-RLS patients without NED significantly higher doubting scores 
compared to controls (P=0.002) were found, whereas a trend towards higher 
MOCI-total scores and checking compulsion scores in comparison with 
controls was evident (P=0.06 and P=0.07, respectively). MOCI scale total 
25 
 
and checking compulsion scores of p-RLS patients with NED and without 
NED did not differ (P=0.45 and P=1, respectively). p-RLS patients with 
NED had significantly higher doubting scores (P=0.021) compared to p-
RLS patients without NED (Figure 6, 7 and 8). No correlation was found 
with RLS or NED clinical characteristics. 
 
2.4 Temperament and Character Inventory 
Regarding temperament and character dimensions, ANOVA test showed 
that the groups differed in harm avoidance (HA) scores (P= 0.03). No 
difference was disclosed in the character dimensions (Table 4). Post-Hoc 
test showed that p-RLS patients with NED compared to controls had 
significantly higher HA scores (P=0.012). p-RLS patients without NED had 
HA scores intermediate between those of controls and those of p-RLS with 
NED, but without significant differences (P=0.28 and P=0.51, respectively) 
(Figure 9). No correlation was found with RLS or NED clinical 
characteristics. 
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We evaluated psychiatric comorbidity in p-RLS patients without and with 
nocturnal eating disorder, untreated with dopamine agonists, analysing 
obsessive-compulsive and personality traits together with mood and anxiety 
disorder, in comparison with a control group matched for age and sex. 
Our study disclosed the following findings: i) p-RLS patients, particularly 
those with NED, have higher mean anxiety factor scores than controls; ii) 
MOCI-total score is significantly higher in p-RLS patients with NED and 
tends to be higher in those without NED compared to controls; iii) p-RLS 
patients with NED had significantly higher doubting and checking 
compulsion scores compared to controls, and significantly higher doubting 
scores compared to p-RLS patients without NED. p-RLS patients without 
NED had significantly higher doubting scores and a trend towards higher 
checking compulsion scores compared to controls; iv) p-RLS patients with 
NED had higher harm avoidance scores in the TCI scale compared to 
controls, whereas p-RLS patients without NED had intermediate HA scores 
but without significant differences compared to other groups. 
We documented an association between RLS with/without NED and anxiety 
disorders confirming literature findings that higher mean 
anxiety/neuroticism factor scores were common in both RLS and NED 
syndrome (Picchietti D and Winkelman JW, 2005; Winkelman JW et al, 
2006; Lee HB et al, 2008; Kalaydjian A et al, 2009; Howell MJ et al, 2009). 
The co-occurrence of RLS and mood and anxiety disorders remains a matter 
of debate: the sets of symptoms co-exist, high anxiety may be a 
predisposing factor for RLS, sleep deprivation inherent in RLS may enhance 
anxiety/neuroticism, and anxiety and RLS may result from a common CNS 
mechanism related to changes in central dopaminergic function. An 
association between a polymorphism in the dopamine transporter and 
anxiety/neuroticism  (Hunnerkopf R et al, 2007) and correlations between 
striatal dopamine D2 receptor densities and anxiety/neuroticism scores (Lee 
IH et al, 2005) suggest an underlying biological component shared by the 
two disorder. Interestingly, our study found higher trait-anxiety rather than 
state-anxiety scores in p-RLS patients compared to controls. 
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We found a significantly higher MOCI-total score in p-RLS patients with 
NED and a trend towards higher MOCI-total score in p-RLS patients 
without NED compared to controls, with an apparent MOCI grading of 
severity from controls to p-RLS patients without NED to p-RLS with NED. 
This is in agreement with a previous study (Provini F et al, 2009) showing, 
at post hoc analysis, that pathological values on the MOCI increased from 
controls to RLS patients without NED to RLS with NED (Provini F et al, 
2009). 
Furthermore, a similar grading of severity from controls to p-RLS patients 
without NED to p-RLS with NED for checking and especially doubting 
subscales was found analysing the subdimensions of the MOCI. Therefore, 
p-RLS patients and especially p-RLS patients with NED reported more 
obsessive-compulsive symptoms than controls. Accordingly, we 
hypothesize that NED represents a true obsessive/compulsive trait in RLS, 
possibly related to dopamine dysfunction. 
Obsessive–compulsive disorder (OCD) is a condition where intrusive 
thoughts or images occur in patients’ minds, provoking anxiety and stress, 
and where a specific behaviour is repeatedly performed to avoid these 
(Cavedini P et al, 2006; Dichter GS et al, 2012). Preclinical animal models 
and functional neuroimaging studies in patients with OCD have 
demonstrated a dysregulation in orbito-fronto-striatal inhibitory control 
pathways. Reward-pathway functions are mediated primarily by the 
ascending mesolimbic DA system that interdigitates with the limbic cortico-
striatal-thalamic circuit in the process of reward information (Haber SN, 
2003; Chau DT et al, 2004; Dichter GS et al, 2012). A reward circuitry 
dysfunction is implicated in compulsive behaviours, including food-seeking 
behaviour (Blum K et al, 1995). Interestingly, a dysfunction of the limbic 
system was also reported by imaging studies in RLS, in terms of 
dopaminergic receptor density (Cervenka S et al, 2006), metabolism (Rizzo 
G et al, 2012), and functional activation (Margariti PN et al, 2012).  
To our knowledge, this is the first study to evaluate personality traits in RLS 
patients with and without NED. Cloninger’s personality theory is based on a 
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biogenetic hypothesis of temperament and character underlying patterns of 
human behaviour. Temperament can be defined as a trait of personality that 
is heritable, biologically and partly genetically determined, developmentally 
stable, uninfluenced by sociocultural learning, and regulated by limbic 
circuits connecting hippocampus, amygdala, hypothalamus, and related 
subcortical structures. Character dimension is what people make of 
themselves intentionally, and in contrast to temperament, character is 
weakly heritable, but is influenced by sociocultural learning. It matures in a 
stepwise manner in increments from infancy through late adulthood, and is 
regulated by the hippocampal formation and cerebral neocortex (Cloninger 
CR, 1994). 
Our study disclosed no significant differences among the three groups in the 
character dimensions of the TCI, but regarding the four dimensions of 
temperament, we detected higher harm avoidance (HA) scores in p-RLS 
patients with NED compared to the control group. HA is a trait of 
personality associated with higher sensitivity of the behavioural inhibition 
system and characterized by excessive worrying, pessimism, shyness, and 
being fearful, doubtful, and easily fatigued. HA refers to a heritable 
tendency to respond intensely to aversive stimuli and their conditioned 
signals, thereby facilitating learning to inhibit behaviour in order to avoid 
punishment, novelty, and frustrative omission of expected rewards 
(Cloninger CR, 1987). Higher HA scores have been found in patients with 
obsessive-compulsive disorder (Bejerot S et al, 1998; Richter MA et al, 
1996; Alonso P et al, 2008; Kim SJ et al, 2009), and in their first degree 
relatives (Ettelt et al., 2008). HA has been associated with increased grey 
matter volume at the level of the left amygdala in female healthy subjects 
(Iidaka et al., 2006), and with different sex-related amygdala resting-state 
functional connectivity (Li Y et al, 2012). Furthermore, HA has been 
associated with different patterns of limbic circuitry activation during risk-
taking tasks (Matthews SC et al, 2004; Paulus MP et al, 2003). 
Although multiple brain neurotransmitter systems are potentially involved 
in HA activity, Cloninger suggested that HA was correlated with high 
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serotonergic activity (Cloninger CR, 1994). However, some studies reported 
that dopaminergic neurotransmission may play a role in regulating neuronal 
activity associated with HA personality trait (Yasuno F et al, 2001; Kim JH 
et al, 2011), and, interestingly, higher HA scores were reported in disorders 
that may show symptoms of OCD (Koo MS et al, 2010), such as Tourette 
syndrome (Horesh N et al, 2008) and idiopathic Parkinson's disease (Tomer 
R, Aharon-Peretz J, 2004; Kaasinen V et al, 2001), whose pathophysiology 
is based on dopaminergic dysfunction. 
Our study also found that p-RLS patients without NED had intermediate HA 
scores compared to other groups, with a grading of severity from controls to 
p-RLS patients without NED to p-RLS with NED similar to MOCI, 
although without significant differences probably due to the low number of 
subjects in each group. 
Accordingly, higher levels of HA, a biologically determined personality 
trait, might constitute a diathesis predisposing individuals stimulated by 
sleep-related motor and autonomic arousal processes to display obsessive-
compulsive symptoms, RLS and then, with increasing severity, compulsive 
nocturnal eating. 
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Our study disclosed the following findings: p-RLS patients, particularly 
those with NED, had increased anxiety factor scores; MOCI-total, doubting 
and checking compulsions, and TCI-HA scores were significantly higher in 
p-RLS patients with NED; p-RLS patients without NED had significantly 
higher MOCI-doubting scores and a trend towards higher checking 
compulsion and HA scores with an apparent grading from controls to p-RLS 
patients without NED to p-RLS with NED. 
We speculate that higher levels of HA, a biologically determined personality 
trait, might constitute a diathesis predisposing individuals stimulated by 
sleep-related motor and autonomic arousal processes to display obsessive-
compulsive symptoms, RLS and then, with increasing severity, compulsive 
nocturnal eating. In this scenario RLS and NED could represent a 
pathological continuum of a single disease entity in which a limbic system 
dysfunction, possibly driven by a dopaminergic impairment, could be the 
underlying pathophysiological mechanism. However, the low statistical 
power of this study precludes a definitive conclusion. We cannot exclude 
that NED may simply be an RLS co-morbidity or that the eating behaviour 
is a sort of ‘‘killing time’’ activity performed in an attempt to recapture 
sleep. In both cases NED seems to occur more readily in biologically 
predisposed individuals, for example those with a particular temperament 
trait such as higher HA scores. 
The relationship between psychiatric comorbidity and nocturnal eating in 
RLS warrants further investigation, especially in prospective studies, and 
obsessive-compulsive symptoms should be analyzed together with 
personality traits. 
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Table 1. Clinical and socio-demographic variables of p-RLS patients with 
NED, p-RLS patients without NED, and controls. No difference was found 
among the three groups (all P>0.05). 
 p-RLS 
patients 
with NED 
p-RLS 
patients 
without  
NED 
Control 
Group 
Age (yrs) mean ± SD 53±11 52±6 52±10 
Men / / / 
Women 10 10 10 
Level of education    
middle school 5 4 4 
upper secondary school 5 6 6 
Occupation    
Employed 7 4 4 
Housewife  3 1 
Professional  2 2 
Retired 3 1 1 
Unemployed   2 
Body mass index mean (±SD) 26±4 27±5 25±6 
Concomitant diseases 7 5 5 
Systemic hypertension 5 2 3 
Thyroid pathologies 2 3 2 
Age at onset of p-RLS (mean ± SD) 42±16 39±14 / 
Positive family history 4 7 / 
RLS Severity (mean ± SD) 19±13 17±10 / 
RLS frequency (in the last three months)    
2-3 times/week 2 1  
4-5 times/week 2   
6-7 times/week 5 9  
1-2 times/month    
3-4 times/month    
2-3 times/year 1   
Daytime p-RLS symptoms 5 7 / 
Medication for p-RLS symptoms Drug-free Drug-free / 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder 
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Table 2. Clinical features of NED in p-RLS patients. 
 
  
 p-RLS patients with NED 
(Number) 
NED onset  
NED onset after p-RLS 4 
NED onset before p-RLS 3 
NED onset concomitant with p-RLS 2 
Unknown 1 
NED frequency  (in the last three month) 
 
every night 2 
3-5 times/week 5 
1-2 times/week 1 
1-2 times/month 2 
1-6 times/year 
 
Number of eating episodes per night 
 
1-2 episodes/night 8 
3-5 episodes/night 2 
    
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder 
 
 
 
36 
 
  
Table 3. Different scores (mean ± standard deviation) on Depression and 
Anxiety Scales in the three groups studied. 
 Controls 
p-RLS 
patients 
without NED 
p-RLS 
patients with 
NED 
P (ANOVA)* 
HAMILTON-D 4.7±2.1 6.9±6.5 9.1±7.4 0.7 
HAMILTON-A 4.7±3.0 14.3±8.4 21.6±8.6 0.0002 
STAI-Y State 
score 31.1±9.5 43.8±14.3 40.4±12.3 0.21 
STAI-Y Trait 
score 32.5±10.9 47.2±13.4 46.4±10.5 0.043 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder; HAMILTON-D= Hamilton scale for Depression; HAMILTON-
A= Hamilton scale for Anxiety; STAI-Y= State-Trait Anxiety Inventory – 
Trait and State version. 
* Corrected for multiple comparisons 
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Table 4. Different scores (mean ± standard deviation) on the Maudsley 
Obsessive Compulsive Inventory (MOCI) and Temperament and Character 
Inventory (TCI) in the three groups studied. 
 Controls 
p-RLS patients 
without NED 
p-RLS patients 
with NED P (ANOVA)* 
MOCI-Total 8±2.6 12.2±5 14.7±3.2 0.004 
MOCI- checking 7.7±13.7 28.6±24.4 34.1±19.7 0.03 
MOCI- cleaning 37.8±13.2 41.4±18.1 42.3±12.7 1 
MOCI- slowness 33.6±7.2 28±16.1 30.9±13 1 
MOCI- doubting 9.8±13.2 42.4±22.3 66.7±19.2 <0.0001 
  TCI-HA 15.6±4.3 20.3±8.1 24.1±4.9 0.03 
 TCI-NS 21.4±5 19.3±7.5 15.7±9.4 0.5 
 TCI-RD 15.4±2.6 14.3±3.3 13.6±4.5 1 
TCI TCI-P 3.8±1.1 4.4±1.5 4.9±2.1 0.7 
 TCI-SD 30.8±2.9 26.4±7.9 26.2±7.5 0.45 
 TCI-C 34.7±3.5 30.5±4.3 30.8±5.5 0.18 
 TCI-ST 21.9±2.1 20.8±2.1 20.5±3.1 0.85 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder; MOCI= Maudsley Obsessive-Compulsive Inventory; TCI= 
Temperament and Character Inventory; HA= Harm Avoidance; NS= 
Novelty Seeking; RD= Reward Dependence; P= Persistence; SD= Self-
Directedness; C= Cooperativeness; ST= Self-Transcendence. 
* Corrected for multiple comparisons 
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Figure 1. Diagnostic Criteria of Restless Legs Syndrome 
 
 
 
International Restless Legs Syndrome Study Group, 1995; Allen RP et al, 
2003 
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Figure 2. Diagnostic Criteria of Sleep-Related Eating Disorder 
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Figure 3. Diagnostic Criteria of Night Eating Disorder (NES) 
 
 
 
From Birketvedt GS et al, 1999 
 
 
 
From Allison CK et al, 2010 
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Figure 4. Post-hoc test (LSD test followed by Bonferroni correction) for 
HAMILTON-A= Hamilton Scale for Anxiety. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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Figure 5. Post-hoc test (LSD test followed by Bonferroni correction) for 
STAI-Y= State-Trait Anxiety Inventory – Trait version. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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Figure 6. Post Hoc test (LSD test followed by Bonferroni correction) for 
Maudsley Obsessive-Compulsive Inventory (MOCI) total scores. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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Figure 7. Post Hoc test (LSD test followed by Bonferroni correction) for 
Maudsley Obsessive-Compulsive Inventory (MOCI)-checking scores. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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Figure 8. Post Hoc test (LSD test followed by Bonferroni correction) for 
Maudsley Obsessive-Compulsive Inventory (MOCI)-doubting scores. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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Figure 9. Post Hoc test (LSD test followed by Bonferroni correction) for 
Temperament and Character Inventory (TCI)-Harm Avoidance scores. 
 
 
p-RLS= Primary Restless Legs Syndrome; NED= Nocturnal Eating 
Disorder. 
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